

Supplementary Table 19: Goodness of fit statistics for IPW comparison of 2L CD patients

Characteristic	Difference (ADA – IFX) ¹	95% CI ¹	Difference (UST – IFX) ¹	95% CI ¹	Difference (VDZ- IFX) ¹	95% CI ¹
Patient Sex	0.02	–0.30, 0.33	0.00	–0.31, 0.31	0.00	–0.31, 0.32
Patient Age	0.02	–0.29, 0.33	0.03	–0.29, 0.34	0.02	–0.29, 0.33
CCI	0.04	–0.27, 0.35	0.04	–0.28, 0.35	0.02	–0.29, 0.33
Number of corticosteroid prescriptions	0.01	–0.30, 0.33	0.03	–0.28, 0.34	0.02	–0.30, 0.33
Number of hospitalizations	0.03	–0.28, 0.34	0.03	–0.29, 0.34	0.01	–0.30, 0.33
Number of comorbidities	0.01	–0.30, 0.33	0.00	–0.31, 0.32	0.01	–0.31, 0.32
Number of injuries in follow-up	0.04	–0.27, 0.36	0.08	–0.23, 0.39	0.02	–0.30, 0.33

ADA = Adalimumab CCI = Charlson Comorbidity Index CD = Crohn’s disease CI = Confidence Interval IFX = Infliximab IPW = inverse probability weighting UST = Ustekinumab VDZ = Vedolizumab

¹Standardized Mean Difference